David Dalvey Sells 25,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Trading Down 1.6%

NASDAQ CELC traded down $2.25 on Wednesday, hitting $139.44. 801,530 shares of the stock were exchanged, compared to its average volume of 798,960. Celcuity, Inc. has a 52-week low of $9.51 and a 52-week high of $151.02. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The company has a market capitalization of $6.74 billion, a price-to-earnings ratio of -36.79 and a beta of 0.09. The company’s 50-day moving average price is $115.27 and its two-hundred day moving average price is $103.28.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.09. Research analysts predict that Celcuity, Inc. will post -3.97 EPS for the current year.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Phase‑III headline: gedatolisib outperformed Novartis’ Piqray and showed a survival benefit in PIK3CA+ metastatic breast cancer — the clinical win is the primary fundamental catalyst that drove recent buying and acquisition speculation. Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy and other firms (Needham) issued positive forecasts and price‑target increases, reinforcing investor confidence and fueling takeover chatter. Guggenheim Keeps Their Buy Rating on Celcuity (CELC) Needham & Company LLC Issues Positive Forecast for Celcuity
• Neutral Sentiment: Valuation debate: commentary asks whether a ~13x one‑year surge leaves meaningful upside from here — this frames mixed investor sentiment despite the clinical win. Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?
• Negative Sentiment: Near‑term estimate trims: HC Wainwright slightly lowered Q1–Q3/Q2 2026 EPS forecasts (small downgrades) — a signal that near‑term cash burn, timing of revenues or costs could be risk factors even as they lift long‑term projections. (Research note released 5/4/2026)
• Negative Sentiment: Technical/profit‑taking pressure: stock is trading near its 1‑year high after a rapid rally; modestly elevated volume and the high headline valuation increase the odds of short‑term pullbacks as some investors lock in gains.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Celcuity during the 4th quarter valued at $42,000. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity during the 3rd quarter valued at $27,000. US Bancorp DE lifted its stake in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. Finally, NBC Securities Inc. acquired a new stake in shares of Celcuity in the 4th quarter valued at $99,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on CELC. Craig Hallum reiterated a “buy” rating and set a $189.00 price objective on shares of Celcuity in a research report on Monday. Citizens Jmp lifted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research report on Monday. Guggenheim lifted their price objective on shares of Celcuity from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup reissued an “outperform” rating on shares of Celcuity in a research note on Monday. Finally, Needham & Company LLC lifted their target price on shares of Celcuity from $122.00 to $157.00 and gave the company a “buy” rating in a research note on Monday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and a consensus target price of $134.50.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.